NCT04671069

Drug Interaction Study of MGL-3196 With Clopidogrel

A Single Center, Open-Label, Drug Interaction Study of MGL-3196 With Clopidogrel in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Madrigal Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether the single and multiple-dose pharmacokinetics (PK) of MGL-3196 are affected by co-administration with clopidogrel in healthy subjects.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	MGL-3196	Administered orally on the morning of Day 1; Multiple-dose administration of 100 mg MGL-3196 on Day 6 until Day 14
DRUG	Clopidogrel	After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11

Timeline

• Start date: 2019-07-26
• Primary completion: 2019-08-30
• Completion: 2019-09-14
• First posted: 2020-12-17
• Last updated: 2020-12-28

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study